JP2016515582A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515582A5
JP2016515582A5 JP2016505551A JP2016505551A JP2016515582A5 JP 2016515582 A5 JP2016515582 A5 JP 2016515582A5 JP 2016505551 A JP2016505551 A JP 2016505551A JP 2016505551 A JP2016505551 A JP 2016505551A JP 2016515582 A5 JP2016515582 A5 JP 2016515582A5
Authority
JP
Japan
Prior art keywords
pyrazol
pyridin
carbonyl
hydroxy
methylbenzonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016505551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515582A (ja
JP6282724B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/031918 external-priority patent/WO2014160810A1/en
Publication of JP2016515582A publication Critical patent/JP2016515582A/ja
Publication of JP2016515582A5 publication Critical patent/JP2016515582A5/ja
Application granted granted Critical
Publication of JP6282724B2 publication Critical patent/JP6282724B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016505551A 2013-03-29 2014-03-26 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用 Active JP6282724B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361806806P 2013-03-29 2013-03-29
US61/806,806 2013-03-29
US201361916715P 2013-12-16 2013-12-16
US61/916,715 2013-12-16
PCT/US2014/031918 WO2014160810A1 (en) 2013-03-29 2014-03-26 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018009987A Division JP6462911B2 (ja) 2013-03-29 2018-01-24 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用

Publications (3)

Publication Number Publication Date
JP2016515582A JP2016515582A (ja) 2016-05-30
JP2016515582A5 true JP2016515582A5 (enExample) 2017-05-18
JP6282724B2 JP6282724B2 (ja) 2018-02-21

Family

ID=50792544

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016505551A Active JP6282724B2 (ja) 2013-03-29 2014-03-26 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2018009987A Active JP6462911B2 (ja) 2013-03-29 2018-01-24 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2018245492A Active JP6640978B2 (ja) 2013-03-29 2018-12-27 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2019235781A Active JP6874114B2 (ja) 2013-03-29 2019-12-26 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018009987A Active JP6462911B2 (ja) 2013-03-29 2018-01-24 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2018245492A Active JP6640978B2 (ja) 2013-03-29 2018-12-27 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用
JP2019235781A Active JP6874114B2 (ja) 2013-03-29 2019-12-26 6−(5−ヒドロキシ−1h−ピラゾール−1−イル)ニコチンアミド誘導体およびphd阻害剤としてのそれらの使用

Country Status (40)

Country Link
US (5) US9040522B2 (enExample)
EP (2) EP3336084B1 (enExample)
JP (4) JP6282724B2 (enExample)
KR (1) KR102376354B1 (enExample)
CN (1) CN105492433B (enExample)
AP (1) AP2015008783A0 (enExample)
AU (1) AU2014241183B2 (enExample)
BR (1) BR112015020350B1 (enExample)
CA (1) CA2903875C (enExample)
CL (1) CL2015002473A1 (enExample)
CR (1) CR20150517A (enExample)
CY (1) CY1120029T1 (enExample)
DK (1) DK2978752T3 (enExample)
EA (1) EA031647B1 (enExample)
EC (1) ECSP15045801A (enExample)
ES (1) ES2660914T3 (enExample)
GE (1) GEP201706761B (enExample)
HR (1) HRP20180341T1 (enExample)
HU (1) HUE038220T2 (enExample)
IL (1) IL240803B (enExample)
JO (1) JO3722B1 (enExample)
LT (1) LT2978752T (enExample)
ME (1) ME03024B (enExample)
MX (1) MX370388B (enExample)
MY (1) MY184218A (enExample)
PE (1) PE20151860A1 (enExample)
PH (1) PH12015502248B1 (enExample)
PL (1) PL2978752T3 (enExample)
PT (1) PT2978752T (enExample)
RS (1) RS56974B1 (enExample)
SG (1) SG11201506749XA (enExample)
SI (1) SI2978752T1 (enExample)
SM (1) SMT201800112T1 (enExample)
TN (1) TN2015000397A1 (enExample)
TR (1) TR201802632T4 (enExample)
TW (1) TWI635084B (enExample)
UA (1) UA118965C2 (enExample)
UY (1) UY35513A (enExample)
WO (1) WO2014160810A1 (enExample)
ZA (1) ZA201506484B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3336084B1 (en) 2013-03-29 2021-03-17 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors
RS60906B1 (sr) 2014-10-06 2020-11-30 Vertex Pharma Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
PT3551622T (pt) 2016-12-09 2020-11-12 Vertex Pharma Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN107163043A (zh) * 2017-06-16 2017-09-15 上海毕得医药科技有限公司 一种吡唑并[1,5‑a]吡啶‑3‑羧酸酯衍生物的合成方法
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CN111918865B (zh) 2018-03-30 2023-10-27 住友化学株式会社 杂环化合物和含有该杂环化合物的有害节肢动物防除组合物
WO2019195739A1 (en) * 2018-04-05 2019-10-10 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN111349077B (zh) * 2019-02-02 2022-06-28 杭州华东医药集团新药研究院有限公司 一种哒嗪衍生物及其制备方法和医药用途
EP4121425A1 (en) * 2020-03-20 2023-01-25 Akebia Therapeutics Inc. Phd inhibitor compounds, compositions, and use
US20230212138A1 (en) * 2020-03-20 2023-07-06 Akebia Therapeutics, Inc. Phd inhibitor compounds, compositions, and their use
CN121085892A (zh) * 2020-03-20 2025-12-09 阿克比治疗有限公司 Phd抑制剂化合物、组合物和用途
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022251563A1 (en) 2021-05-27 2022-12-01 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
JP7710897B2 (ja) * 2021-06-01 2025-07-22 三菱ガス化学ネクスト株式会社 1-アルキル-5-ヒドロキシピラゾールの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663327A (en) 1984-05-23 1987-05-05 Bayer Aktiengesellschaft 1-heteroaryl-4-aryl-pyrazolin-5-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004022540A2 (en) * 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
CA2619262A1 (en) 2005-08-19 2007-02-22 Astrazeneca Ab Pyrazolone derivatives for the treatment of tuberculosis
NZ601730A (en) * 2006-06-26 2014-04-30 Akebia Therapeutics Inc Prolyl hydroxylase inhibitors and methods of use
PL2090570T3 (pl) * 2006-09-05 2012-03-30 Kyowa Hakko Kirin Co Ltd Pochodna imidazolu
DE102006050515A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
PT2439205E (pt) 2006-12-29 2015-07-16 Abbvie Deutschland Compostos de carboxamida e seus usos como inibidores de calpaína
DE102007044032A1 (de) 2007-09-14 2009-03-19 Bayer Healthcare Ag Substituierte heterocyclische Verbindungen und ihre Verwendung
JP5557832B2 (ja) * 2008-03-18 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 置換4−ヒドロキシピリジン−5−カルボキサミド
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
MX2011007061A (es) * 2008-12-29 2011-12-16 Sanofi Sa Derivados de 2 piridin- 2-il-pirazol-3 (2h)-ona, su preparacion y aplicacion terapeutica.
HRP20140680T1 (hr) * 2008-12-29 2014-10-10 Sanofi Derivati 2-piridin-2-ilpirazol-3(2h)-ona, njihovo dobivanje i njihova upotreba u terapiji kao aktivatora hif
EP3336084B1 (en) * 2013-03-29 2021-03-17 Takeda Pharmaceutical Company Limited 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide derivatives and their use as phd inhibitors

Similar Documents

Publication Publication Date Title
IL244787B (en) Polymorph c of n-((4,6-dimethyl-2 oxo-1,2-dihydropyridine-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl -4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide monohydrochloride, methods for its preparation, medical preparations containing it and its use
SI2978752T1 (en) 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD
JP2016506960A5 (enExample)
JP2016040288A5 (enExample)
JP2013543896A5 (enExample)
JP2016506962A5 (enExample)
CL2015000332A1 (es) Forma cristalina a y racemato cristalino de 1-(5'-(5-(3,5-dicloro-4-fluorofenil)-5-(trifluorometil)-4,5-dihidroisoxazol-3-il)-3'h-espiro[azetidin-3,1'-isobenzofuran]-1-il)-2-(metilsulfonil)etanona; procedimiento de preparacion de la forma cristalina a; composicion que la comprende; y su uso para el tratamiento de una infeccion o infestacion parasitaria.
JP2019509276A5 (enExample)
JP2016530213A5 (enExample)
JP2013531031A5 (enExample)
JP2016505637A5 (enExample)
JP2019512535A5 (enExample)
JP2017513894A5 (enExample)
MY190878A (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
JP2012522764A5 (enExample)
JP2014505107A5 (enExample)
JP2011037901A5 (enExample)
JP2015524472A5 (enExample)
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
MX2014003623A (es) Monohidrato de mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol -2-il]-2-[4-(2-piridinil)-fenil]-n-metilacetamida con un intervalo de distribucion de tamaño de particula especifica y un intervalo de area superficial especifica para uso en formulaciones farmaceuticas.
JP2013540712A5 (enExample)
JP2015516427A5 (enExample)
JP2016529245A5 (enExample)
RU2017120858A (ru) Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина
JP2016523260A5 (enExample)